Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1992;30(4):321-4.
doi: 10.1007/BF00686303.

Phase I trial of a 72-h continuous-infusion schedule of fazarabine

R Amato  1 , D Ho, S Schmidt, I H Krakoff, M Raber
Affiliations
Clinical Trial

Phase I trial of a 72-h continuous-infusion schedule of fazarabine

R Amato et al. Cancer Chemother Pharmacol. 1992.

Abstract

Fazarabine (Ara-AC), a structural analog derived from the antitumor nucleoside cytosine arabanoside (Ara-C) and 5-azacytidine (5-AC), was studied in a phase I clinical trial. Doses ranging from 0.2 to 2.0 mg m-2 h-1 were given intravenously over 72 h every 28 days. The maximum tolerated dose (MDT) was 2.00 mg m-2 h-1. The dose-limiting toxicity was myelosuppression, with granulocytopenia being quantitatively more important than thrombocytopenia or anemia. Nonhematologic toxicity was minimal. Associated with the solvent dimethylsulfoxide (DMSO) was a bitter taste and a garlic-like odor.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Cancer Res. 1986 Feb;46(2):831-8 - PubMed
    1. Invest New Drugs. 1985;3(4):323-9 - PubMed
    1. Invest New Drugs. 1987 Dec;5(4):315-28 - PubMed
    1. Invest New Drugs. 1985;3(4):331-4 - PubMed
    1. Biochem Pharmacol. 1977 Dec 15;26(24):2469-72 - PubMed

Publication types